Olema Pharmaceuticals Inc OLMA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 10:51 AM EDT
10.32quote price arrow down-0.53 (-4.88%)
Volume
170,805
52 week range
5.02 - 17.79
Loading...
  • Open11.40
  • Day High11.40
  • Day Low10.21
  • Prev Close10.85
  • 52 Week High17.79
  • 52 Week High Date11/08/23
  • 52 Week Low5.02
  • 52 Week Low Date05/30/23

Key Stats

  • Market Cap577.04M
  • Shares Out55.91M
  • 10 Day Average Volume0.71M
  • Dividend-
  • Dividend Yield-
  • Beta2.11
  • YTD % Change-26.02

KEY STATS

  • Open11.40
  • Day High11.40
  • Day Low10.21
  • Prev Close10.85
  • 52 Week High17.79
  • 52 Week High Date11/08/23
  • 52 Week Low5.02
  • 52 Week Low Date05/30/23
  • Market Cap577.04M
  • Shares Out55.91M
  • 10 Day Average Volume0.71M
  • Dividend-
  • Dividend Yield-
  • Beta2.11
  • YTD % Change-26.02

RATIOS/PROFITABILITY

  • EPS (TTM)-2.16
  • P/E (TTM)-4.78
  • Fwd P/E (NTM)-4.35
  • EBITDA (TTM)-104.584M
  • ROE (TTM)-42.82%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Olema Pharmaceuticals Inc

 

Profile

MORE
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of...
Ian Clark
Independent Chairman of the Board
Sean Bohen M.D., Ph.D.
President, Chief Executive Officer, Director
Shane Kovacs
Chief Operating and Financial Officer
John Moriarty Jr., J.D.
Executive Vice President, Chief Legal Officer and Secretary
Address
780 Brannan Street
San Francisco, CA
94103
United States

Top Peers

SYMBOLLASTCHG%CHG
LYEL
Lyell Immunopharma Inc
2.60+0.10+4.00%
GHRS
GH Research PLC
12.02+0.03+0.25%
PHAT
Phathom Pharmaceuticals Inc
10.48+0.38+3.76%
AVTE
Aerovate Therapeutics Inc
20.86-0.18-0.86%
IGMS
IGM Biosciences Inc
9.15-0.19-2.03%